Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 27, 2015 6:31 AM ET

Pharmaceuticals

Company Overview of Dermira, Inc.

Company Overview

Dermira, Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States. The company’s late-stage product candidates comprise Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor, which is in Phase III clinical trial for the treatment of moderate-to-severe plaque psoriasis; DRM04, a small-molecule anticholinergic product that has completed a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01, a sebum inhibitor, which has completed a Phase IIa clinical trial for the treatment of acne. Its early-stage progra...

275 Middlefield Road

Suite 150

Menlo Park, CA 94025

United States

Founded in 2010

34 Employees

Phone:

650-421-7200

Key Executives for Dermira, Inc.

Co-Founder, Chairman and Chief Executive Officer
Age: 62
Total Annual Compensation: $371.3K
Co-Founder and Executive Vice President of Product Development
Age: 52
Total Annual Compensation: $300.0K
Chief Financial Officer and Chief Operating Officer
Age: 46
Total Annual Compensation: $224.7K
Compensation as of Fiscal Year 2014.

Dermira, Inc. Key Developments

Dermira, Inc. Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Dermira, Inc. reported consolidated earnings results for the first quarter ended March 31, 2015. For the quarter ended March 31, 2015, Dermira reported net loss of $14.0 million or $0.57 per basic and diluted share, compared with net loss of $8.5 million or $9.56 per basic and diluted share for the same period in 2014. Loss from operations was $14.2 million against $8.5 million a year ago.

Dermira, Inc. to Report Q1, 2015 Results on May 11, 2015

Dermira, Inc. announced that they will report Q1, 2015 results After-Market on May 11, 2015

Dermira, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Earnings Guidance for the Year 2015

Dermira, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, loss from operations was $6,782,000 against $6,692,000 last year. Net loss was $6,727,000 compared to $6,714,000 a year ago. Net loss per basic and diluted share was $0.29 against $7.56 last year. Revenue for the quarter ended December 31, 2014 was $7.3 million. For the year ended, loss from operations was $31,698,000 against $22,303,000 last year. Net loss was $31,875,000 compared to net loss of $22,350,000 last year. Net loss per basic and diluted share was $4.96 against $27.03 last year. Revenue for the year ended December 31, 2014 was $7.3 million. For the year 2015, the company expects non-GAAP operating expenses for 2015, excluding the impact of stock-based compensation expense, to be in the range of $80 million to $85 million and to have approximately $90 million in cash and cash equivalents and investments as of year-end 2015.

Similar Private Companies By Industry

Company Name Region
InterHealth Nutraceuticals, Inc. United States
Mt. Cook Pharma, Inc. United States
Immune Modulation, Inc. United States
Saladax Biomedical, Inc. United States
Elorac, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
September 19, 2014
--
Private Placement
August 15, 2014
--
Private Placement
July 3, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Dermira, Inc., please visit www.dermira.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.